{"disease":{"id":"choroideremia","name":"choroideremia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04795206","title":"Natural Disease Progression in Participants With Choroideremia","phase":"","overall_status":"COMPLETED","enrollment_count":1178,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT03584165","title":"Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":330,"lead_sponsor_name":"NightstaRx Ltd, a Biogen Company","has_results":false},{"nct_id":"NCT03359551","title":"Natural History of the Progression of Choroideremia Study","phase":"","overall_status":"COMPLETED","enrollment_count":319,"lead_sponsor_name":"NightstaRx Ltd, a Biogen Company","has_results":false},{"nct_id":"NCT03496012","title":"Efficacy and Safety of BIIB111 for the Treatment of Choroideremia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":169,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT06375239","title":"Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration","phase":"","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Ray Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03507686","title":"A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT05258032","title":"Structural and Functional Characterization of Rare Ocular Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Barcelona Macula Foundation","has_results":false},{"nct_id":"NCT04750785","title":"A Study to Assess Choroideremia (CHM) Health Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT02407678","title":"REP1 Gene Replacement Therapy for Choroideremia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT02341807","title":"Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Spark Therapeutics, Inc.","has_results":true},{"nct_id":"NCT04483440","title":"Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":13,"lead_sponsor_name":"4D Molecular Therapeutics","has_results":false},{"nct_id":"NCT05158049","title":"Longitudinal Study of a Bionic Eye","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":7,"lead_sponsor_name":"Center for Eye Research Australia","has_results":false},{"nct_id":"NCT03406416","title":"Study of a Suprachoroidal Retinal Prosthesis","phase":"NA","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Mobius Medical Pty Ltd.","has_results":false}],"total":13},"guidelines":[],"source":"Drug Landscape verified database"}